Ménière's Disease

Ménière's disease is a chronic condition of the inner ear in which fluid builds up where it shouldn't, distorting the hearing and balance organs. Episodes are dramatic but self-limiting: the patient experiences intense spinning vertigo lasting two to twelve hours, with a drop in hearing on one side, loud ringing, and a feeling of pressure in the ear. Between episodes the patient is usually well, although hearing can fluctuate and a baseline imbalance is common.

Over years, hearing on the affected side typically declines progressively. The condition can affect one ear (most common) or both. There is no cure, but a stepwise approach — starting with diet and lifestyle, escalating to medications and, in refractory cases, procedures — controls symptoms for most patients.

Ménière's disease is an episodic peripheral vestibular disorder defined by the simultaneous involvement of the vestibular and cochlear partitions of one (sometimes both) inner ear. Estimated prevalence is 17–46 per 100,000, with a peak onset between 40 and 60 years of age.1 The condition is named for Prosper Ménière, who in 1861 first attributed the syndrome to the inner ear rather than to a cerebral cause as had been previously assumed.

The defining pathology, demonstrated by Hallpike and Cairns in their seminal 1938 temporal-bone study, is endolymphatic hydrops — distension of the membranous labyrinth by an accumulation of endolymph, particularly affecting the scala media of the cochlea and the saccule.2Whether hydrops itself causes Ménière's symptoms or is a downstream marker has been debated; temporal-bone studies show hydrops in essentially every clinical case, but also in some asymptomatic individuals, which complicates the causal argument.3

Most cases are idiopathic. Around 10% of cases are familial, with a polygenic or autosomal-dominant inheritance pattern emerging in genome-wide studies.7Secondary causes — "Ménière's syndrome" rather than disease — include autoimmune inner-ear disease, otosyphilis, post-traumatic hydrops, and large vestibular aqueduct syndrome.

The pathophysiological cascade is best modelled as impaired endolymph homeostasis: production by the stria vascularis exceeds absorption by the endolymphatic sac, the membranous labyrinth distends, and an acute rise in endolymphatic pressure either ruptures Reissner's membrane locally or transiently opens K⁺ channels at the hair-cell apex — in either case the result is paradoxical hair-cell depolarisation followed by transient functional loss. The hydrops itself is a chronic structural change; the acute attack is a biochemical event superimposed upon it.3

In vivo demonstration of hydrops became possible after Nakashima's 2007 description of intratympanic-gadolinium MRI, which highlights perilymph and reveals the endolymphatic spaces as filling defects.4The technique is not required for diagnosis under current criteria, but it has been useful for confirming hydrops in atypical cases, for distinguishing Ménière's from vestibular migraine in refractory presentations, and for research into the natural history of hydrops. The 3T delayed-gadolinium protocol is the current standard.

Three observations from the temporal-bone literature continue to shape clinical practice. First, saccular hydrops can be isolated — the inferior-division vestibular afferents are preferentially affected, which is why cVEMPs are commonly abnormal in Ménière's while oVEMPs may be preserved. Second, contralateral hydrops emerges on histology before it manifests clinically; bilateral involvement increases over time and reaches 15–40% by 20 years from onset. Third, the endolymphatic sac itself is reduced in size in many patients — the structural basis for the sac-decompression and duct-blockage surgical procedures.1

The figure above is a cross-section through one turn of the cochlea — the snail-shaped hearing organ. Inside, there are three fluid-filled chambers separated by thin membranes. The middle chamber, scala media, contains a special fluid (endolymph) with a high concentration of potassium. The chambers above and below contain a different fluid (perilymph) with low potassium.

In Ménière's disease, endolymph accumulates and the middle chamber swells, stretching the membrane above it (Reissner's membrane). When the pressure becomes too great, this membrane ruptures, the two fluids mix, and the hair cells — which are exquisitely sensitive to potassium concentration — misfire wildly. That is the Ménière's attack.

The membrane eventually heals and normal fluid balance is restored, which is why the attacks are episodic. But the damage is cumulative: with each cycle, a little more hearing is permanently lost.

The cochlea is divided into three parallel scalae running its full length: scala vestibuli (perilymph, continuous with the vestibule), scala media (endolymph, an enclosed compartment with a high K⁺/low Na⁺ profile maintained by the stria vascularis), and scala tympani (perilymph, continuous with the round window niche). Reissner's membrane separates scala vestibuli from scala media; the basilar membrane (with the organ of Corti on top) separates scala media from scala tympani.1

Endolymph is produced primarily by the stria vascularis at a steady rate and absorbed by the endolymphatic sac. When that balance is upset — by sac fibrosis, hypoplastic sac anatomy, autoimmune injury, viral infection, vascular insufficiency, or other proposed causes — endolymph accumulates, scala media distends, and Reissner's membrane bulges upward. Step through the figure to see the progression: normal anatomy → early hydrops (mild distension) → severe hydrops (large distension, hair cells stressed) → acute rupture (membrane fails, K⁺ contaminates perilymph, hair cells depolarise, attack ensues).3

The vestibular sequelae mirror this. The saccule, anatomically contiguous with scala media via the ductus reuniens, distends in parallel and presses against the macula utriculi and the lateral canal wall. With each episode, saccular function is progressively compromised, which is why cVEMPs deteriorate across the disease course.

The hydrops-as-cause hypothesis has limits worth understanding. Merchant et al.'s reanalysis of the temporal-bone literature noted that hydrops is found postmortem in approximately 9% of subjects who never reported Ménière's symptoms — and Ménière's symptoms can occur in the absence of demonstrable hydrops.3 The most parsimonious current view is that hydrops is a marker for a broader endolymphatic dysregulation; the symptomatic attack requires a second event (membrane rupture, transient ion-channel opening, or vascular precipitant) that the hydrops makes possible but does not guarantee.

For the clinician, the practical consequences are three. First, in-vivo MRI demonstration of hydrops (post-gadolinium) supports but does not confirm a diagnosis of Ménière's.4 Second, the goal of medical therapy is to reduce endolymph accumulation (diuretics, low-salt diet, betahistine) rather than to treat the attack itself. Third, in refractory disease the surgical target is the endolymphatic sac — decompression or duct-blockage procedures aim to restore endolymph absorption capacity.11

A hearing test in Ménière's disease almost always shows worse hearing on one side, and the pattern is unusual: the deepest sounds (low frequencies) are affected most. Most forms of hearing loss show the opposite pattern, with high frequencies affected first. This "upside-down" loss is one of the most useful clues.

The Bárány/AAO-HNS 2015 criteria require audiometric documentation of low-to-medium-frequency sensorineural hearing loss in the affected ear for the diagnosis of definite Ménière's disease.5 The required pattern, in any of the inter-ictal or peri-ictal recordings, is: pure-tone average across 500, 1000, and 2000 Hz at least 30 dB worse on the affected side than on the contralateral side (or 35 dB if the contralateral ear is also affected, with additional criteria).

Three caveats deserve attention. First, the loss fluctuates in early disease — a single normal audiogram does not exclude Ménière's; serial audiometry across attacks is more revealing than any single recording. Second, the pattern flattens with disease progression; late-stage Ménière's often shows a moderately severe pancochlear loss that no longer demonstrates the upsloping configuration. Third, similar low-frequency SNHL patterns can be seen in autoimmune inner-ear disease, large vestibular aqueduct syndrome, and intracranial hypotension — the audiogram supports the diagnosis but does not make it alone.1

In stage 1 Ménière's, hearing recovers between attacks — sometimes to normal — and the audiogram is a snapshot, not a baseline. Schedule serial audiometry particularly close to attack times if achievable; the fluctuation is itself diagnostic. Stage 2 brings persistent low-frequency loss that no longer recovers; stage 3 brings expansion to mid- and high frequencies; stage 4 (end-stage) is a flat moderate-to-severe sensorineural pattern with speech discrimination scores out of proportion to pure-tone thresholds and a "dead ear" phenomenon in some patients. The Bárány/AAO-HNS criteria use the four-tone pure-tone average (500, 1000, 2000, 3000 Hz) for staging.5

Electrocochleography (ECochG) measures the summating potential (SP) and the action potential (AP) of the cochlear nerve. An elevated SP:AP ratio (commonly >0.4–0.5) supports a diagnosis of endolymphatic hydrops but is neither sensitive nor specific enough to be a primary diagnostic test — useful as supportive evidence in equivocal cases.

The diagnosis is made by the doctor recognising the pattern: episodic vertigo lasting hours, hearing changes on one side, ringing, and pressure in the ear. There is no single test — a hearing test, MRI, and balance tests are usually done to support the diagnosis and rule out other things.

The 2015 international consensus criteria (Bárány Society, Japan Society for Equilibrium Research, EAONO, AAO-HNS, Korean Balance Society) define two categories:5

Definite Ménière's disease:

1. Two or more spontaneous episodes of vertigo, each lasting 20 minutes to 12 hours.
2. Audiometrically documented low- to medium-frequency sensorineural hearing loss in one ear, defining the affected ear, on at least one occasion before, during, or after one of the episodes of vertigo.
3. Fluctuating aural symptoms (hearing loss, tinnitus, or fullness) in the affected ear.
4. Not better accounted for by another vestibular diagnosis.

Probable Ménière's disease: Two or more episodes of vertigo or dizziness, each lasting 20 minutes to 24 hours; fluctuating aural symptoms; not better accounted for by another vestibular diagnosis. The probable category accommodates patients with the clinical picture but without audiometric confirmation of hearing loss.

Notably, vertigo episodes outside the 20-minute to 12-hour window should redirect the differential: shorter than 20 minutes suggests vestibular migraine or TIA; longer than 24 hours suggests AUVP or stroke.

The 2015 criteria represent a deliberate departure from the 1995 AAO-HNS criteria, broadening the category of probable disease, requiring no specific test other than audiometry, and explicitly framing the diagnosis as one of pattern recognition rather than exclusion. In practice, three differentials cost the most diagnostic mistakes. Vestibular migraine — particularly in patients who lack a migraine history, or in whom auditory symptoms are mild — accounts for many cases initially labelled Ménière's; the temporal pattern of episodes (longer in Ménière's) and the presence or absence of documented hearing loss is the cleanest discriminator. Autoimmune inner ear disease can produce bilateral fluctuating SNHL with vestibular symptoms and progresses faster than Ménière's. Vestibular schwannoma, while not typically episodic, can present with a single attack of acute vertigo plus unilateral hearing loss — image with gadolinium-enhanced MRI in any unilateral SNHL of unclear cause.

Familial Ménière's, while uncommon (≈10%), warrants pedigree analysis when present.7 An autosomal-dominant inheritance pattern with incomplete penetrance is the most common picture; the underlying genes are heterogeneous, and large-scale GWAS are emerging.

Treatment starts conservatively and escalates only if the patient continues to have attacks. The first steps — cutting salt, caffeine, and alcohol; managing stress; taking a water tablet (diuretic) — help around half of patients. If attacks persist, medications such as betahistine are added, then injections into the ear, then in rare cases surgery.

During an attack, the patient should lie still, take an anti-sickness tablet, and wait it out. Most attacks resolve within a few hours. Between attacks, vestibular rehabilitation can help with any baseline imbalance.

The AAO-HNS 2020 clinical practice guideline organises management as a stepwise ladder.6 Begin at the lowest effective rung and escalate only with documented failure.

1. Lifestyle:low-salt diet (typically <1500 mg sodium/day), reduction of caffeine, alcohol, and smoking. Stress and sleep optimisation. Counselling on the natural history. Symptomatic treatment of acute attacks with antihistamines or benzodiazepines as needed.
2. Diuretics: typically thiazides (e.g. hydrochlorothiazide–triamterene) — weak evidence but low cost and good safety profile.
3. Betahistine: a histamine H₃-antagonist / weak H₁-agonist, widely used in Europe and parts of Asia, not FDA-approved in the US. The BEMED trial found no significant benefit over placebo for vertigo attack frequency at high or standard doses, although some patients report subjective benefit.8
4. Intratympanic corticosteroids: (typically dexamethasone) inject into the middle ear through the tympanic membrane. Useful for vertigo control with hearing preservation. Cochrane evidence supports a modest benefit.9
5. Intratympanic gentamicin: aminoglycoside preferentially toxic to vestibular hair cells. Effective for vertigo control in ≈80–90% of refractory cases, with a 25% risk of further sensorineural hearing loss.10 Avoid in bilateral disease (bilateral vestibular failure is a catastrophic outcome).
6. Surgery: endolymphatic sac decompression, endolymphatic duct blockage, or — as last resort and only in unilateral disease with non-serviceable hearing — vestibular nerve section or labyrinthectomy. Surgical evidence is mostly observational; the Cochrane review noted insufficient high-quality RCT data.11

Vestibular rehabilitation has a place between attacks for patients with persistent inter-ictal imbalance; it does not prevent attacks but accelerates compensation for any cumulative vestibular loss.

The hardest decisions in Ménière's management cluster at the boundary between intratympanic steroid and intratympanic gentamicin. Both deliver drug directly to the inner ear; gentamicin is more effective for vertigo control but ototoxic. The decision pivots on hearing status: serviceable hearing on the affected side argues for trying intratympanic steroid first; non-serviceable hearing makes gentamicin a reasonable early step. A network meta-analysis suggested IT gentamicin gives the highest probability of complete vertigo control, with IT steroid plus betahistine second, both well ahead of placebo.10

Three practical considerations in long-term care. First, contralateral disease is the rate-limiting threat — by 20 years from onset, 15–40% of patients have developed bilateral involvement, and patients on the gentamicin track must be re-evaluated before any contralateral intervention. Second, the natural history is favourable for many patients: attacks may "burn out" over years, with progressive hearing loss but reducing vertigo frequency — a course that argues for patience before destructive procedures. Third, comorbid vestibular migraine is common and often underdiagnosed; refractory disease that responds to migraine prophylaxis deserves reconsideration of the primary diagnosis.1

Drop attacks (Tumarkin's otolithic crises) — sudden falls without warning or loss of consciousness, attributed to abrupt utricular dysfunction — are a feature of advanced disease and an indication to escalate definitively. Intratympanic gentamicin reliably abolishes Tumarkin attacks; their persistence is one of the few absolute indications for surgical destruction of the labyrinth.